ECRM recruits new vice president for health and beauty
CLEVELAND A former executive from the joint venture between Johnson & Johnson and Merck will soon become vice president of ECRM’s health and beauty care category, ECRM announced Thursday.
Paul Nunnari’s 25 years of previous experience include terms as vice president of sales at Johnson & Johnson Merck-Joint Venture, vice president of sales for McNeil Consumer Healthcare and vice president of trade development for the Johnson & Johnson Consumer Group. He also served as vice president of sales for the start-up company Ultreo, as well as serving on advisory boards of organizations such as the National Association of Chain Drug Stores.
ECRM said that it looked forward to his positive effect on its health and beauty care category.
Study suggests effects of ragweed increased due to climate change
MILWAUKEE Global climate change is believed to be making ragweed season worse for allergy sufferers, according to report released by the American Academy of Allergy, Asthma and Immunology released Tuesday.
Recent studies suggest that increasing temperatures and carbon dioxide levels are already resulting in longer ragweed seasons and more concentrated pollen counts. The Journal of Allergy and Clinical Immunology has devoted its September issue to exploring the effects of climate change on allergic disease—including ragweed allergy.
That’s not good news for the estimated 36 million Americans who suffer from ragweed allergy, the primary cause of fall allergy symptoms. Ragweed season unofficially begins Aug. 15.
Researchers have decisively linked climate change to “longer pollen seasons, greater exposure and increased disease burden for late summer weeds such as ragweed,” noted Richard Weber, and chairman of the AAAAI Aerobiology Committee, citing among other findings that increased carbon dioxide has resulted in pollen production increases of between 61 percent and 90 percent in some ragweed varieties.
According to data from the AAAAI one ragweed plant can produce 1 billion pollen grains in an average season. Due to the grains’ light weight, they can travel up to 400 miles with the breeze, leaving virtually no outdoor place ragweed-free.
NAD finds ameal bp safe, recommends advertising adjustments
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Tuesday recommended that Calpis USA modify certain advertising claims for the product “ameal bp,” a dietary supplement aimed at aiding in controlling high blood pressure.
NAD determined that the advertiser provided a reasonable basis for claiming that ameal bp has been clinically shown to help maintain healthier blood pressure and that it is safe and has no side effects.
NAD, however, recommended that the advertiser curtail the number of studies used to support the ameal bp product from as many as 15 to the three clinical studies NAD deemed relevant and reliable, and that Calpis should reference a “healthier,” rather than “healthy,” blood-pressure range.
Finally, NAD recommended that the advertiser more prominently, clearly and conspicuously display the qualifier that “ameal bp is not a prescription drug and is not intended to replace your current medications.”
The company, in its advertiser’s statement, said that it appreciates the opportunity to participate in NAD’s self-regulatory process. “Calpis accepts NAD’s decision and will implement NAD’s recommendations in all future advertising for ameal bp,” Calpis said.